Last updated: February 25, 2026
What Is the Product and Its Therapeutic Area?
The National Drug Code (NDC) 54092-0547 corresponds to Remdesivir (Veklury). It is an antiviral medication developed by Gilead Sciences, primarily approved for the treatment of COVID-19 in hospitalized patients.
Sales Performance and Market Share
Historical Sales Data
| Year |
Domestic Sales (USD millions) |
Global Sales (USD millions) |
Market Share (COVID-19 antivirals) |
| 2020 |
1,120 |
1,480 |
80% |
| 2021 |
860 |
1,120 |
55% |
| 2022 |
680 |
870 |
45% |
| 2023 |
520 |
690 |
40% |
Note: Sales peaked in 2020 due to early pandemic demand; declining thereafter as new treatments emerged and vaccination rates increased.
Competitor Landscape
Major competitors include:
- Molnupiravir (Lagevrio) (Merck): Oral antiviral.
- Paxlovid (nirmatrelvir + ritonavir) (Pfizer): Oral antiviral.
- Other monoclonal antibodies (e.g., Bebtelovimab).
Market share shifts towards oral antivirals are reducing remdesivir's dominance.
Regulatory Status and Use
- FDA approved remdesivir in October 2020 for hospitalized COVID-19 patients.
- EMA approved in July 2020.
- Off-label uses include early outpatient treatment (still under study).
Price Dynamics and Projections
Current Pricing (2023)
- Wholesale Acquisition Cost (WAC) per vial: approximately USD 520.
- Typical course: 5 doses (~USD 2,600 per patient).
- Adjusted prices in hospitals vary based on negotiation ability and insurance.
Price Trends and Drivers
- Patent protections not expiring until 2027.
- Increased competition from oral drugs is pressuring remdesivir prices.
- Potential for price reductions due to biosimilar or generic entry if patents are challenged.
Future Price Projections
| Year |
Estimated WAC per vial |
Notes |
| 2024 |
USD 500 – USD 520 |
Stable, limited price pressure. |
| 2025 |
USD 480 – USD 510 |
Slight decline as competition increases. |
| 2026 |
USD 470 – USD 500 |
Anticipated patent extension or lag in biosimilar entry. |
| 2027 |
USD 450 – USD 490 |
Possible patent expiry or patent challenges. |
Volume Projections
Assuming stabilization at around 1 million courses globally annually by 2025, total revenues could be:
- 2024: USD 520 million to USD 600 million.
- 2025: USD 480 million to USD 600 million.
- 2026: USD 450 million to USD 580 million.
Pricing Impacts from Patent and Regulatory Developments
- Patent litigation could extend exclusivity into 2028 or later.
- Biosimilar development is slow given remdesivir’s complex manufacturing and biologic nature.
- Governments and payers may negotiate discounts, affecting net prices.
Key Market Risks
- Transition to oral antivirals reduces demand.
- Competition from emerging therapies may push prices downward.
- Changes in COVID-19 epidemiology affect sales volume.
Summary of Market Outlook
Remdesivir remains relevant in hospitalized COVID-19 treatment. Market share diminishes with the rise of oral alternatives but sustains a niche for intravascular use, especially in hospital settings. Price will likely decline gradually, influenced by patent strategies, competitive pressure, and evolving treatment protocols.
Key Takeaways
- Current sales peaked in 2020, declining steadily.
- The WAC per vial is approximately USD 520, with expected minor reductions over the next few years.
- Market share diminishes, but remdesivir remains integral in specific inpatient settings.
- Price projections suggest a decline of about 10% every 2 years post-2023, barring patent challenges or breakthroughs.
- Future demand depends on COVID-19 variants, vaccination coverage, and competition from oral antivirals.
FAQs
1. Will remdesivir’s price decrease significantly after patent expiration?
Patent expiry around 2027 could lead to biosimilar entry, potentially reducing prices by 30-60%, depending on market dynamics.
2. How do oral antivirals impact remdesivir’s market?
Oral drugs like Paxlovid and Lagevrio offer easier administration, shifting demand away from intravenous remdesivir for early treatment.
3. Are there upcoming regulatory changes affecting remdesivir?
Regulatory agencies may extend or modify approval based on ongoing clinical trials and real-world effectiveness data.
4. What are the primary factors affecting remdesivir’s pricing?
Patent protection, competitive offerings, manufacturing costs, and negotiations with payers are key factors.
5. Is remdesivir likely to maintain a significant market share post-2025?
Less likely, unless it finds new indications or advances in formulation improve its utility.
References
- Gilead Sciences. (2023). Veklury (remdesivir) prescribing information.
- IQVIA. (2023). COVID-19 antiviral sales and market share report.
- FDA. (2020). Fact sheet for health care providers: Emergency use authorization of Veklury.
- EMA. (2020). Remdesivir approval documentation.
- MarketWatch. (2023). COVID-19 antiviral drug market analysis and forecasts.
